Actinogen Medical Limited (AU:ACW)
ASX:ACW
Want to see AU:ACW full AI Analyst Report?
ACW Stock Chart & Stats
AU$0.04
>-AU$0.01(-3.85%)
At close: 4:00 PM EST
AU$0.04
>-AU$0.01(-3.85%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.07
Previous CloseN/A
Volume244.11K
Average Volume (3M)6.03M
Market Cap
AU$118.95M
Enterprise ValueAU$119.44M
Total Cash (Recent Filing)AU$6.53M
Total Debt (Recent Filing)AU$366.31K
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,717,091,600
10 Day Avg. Volume4,755,726
30 Day Avg. Volume6,028,147
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.74
Price to Sales (P/S)12.48
P/FCF Ratio-9.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$5.50M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageReported low debt-to-equity implies limited financial leverage, reducing solvency risk and preserving flexibility to fund clinical programs. Over the next 2–6 months this balance-sheet strength supports continuity of operations and provides optionality for targeted strategic partnerships or capital when needed.
Differentiated Clinical AssetXanamem’s specific mechanism (11β-HSD1 inhibition) and focused programs in Alzheimer’s and major depressive disorder give Actinogen a clear scientific differentiation. That focused clinical strategy supports durable partner interest, streamlined trial design and licensing potential that persists beyond short-term market cycles.
High Reported Gross Margin PotentialA reported 100% gross profit margin indicates that, if commercialized or monetized via licensing, the asset could support very high incremental margins. For a small clinical-stage biotech this structural margin potential enhances long-term economics of partnerships, royalties and commercialization outcomes despite current losses.
Bears Say
Declining RevenueA sharp revenue decline (-39.16%) reflects weakening top-line momentum and limited commercial inflows. Persistent contraction constrains the company’s ability to scale R&D without external funding, increasing execution risk for multi-stage clinical programs over the coming months and complicating strategic planning.
Negative Cash FlowsNegative operating and free cash flows, with free cash flow declining -13.01%, indicate ongoing cash burn that erodes reserves. This structural cash generation weakness forces reliance on outside financing, limits runway for trials, and raises the probability of dilutive capital raises within a 2–6 month timeframe.
Funding Model Reliant On RaisesDependence on periodic equity raises rather than product revenue makes funding intermittent and dilutive. This business-model reality heightens financing risk, undermines long-term financial stability, and makes program execution contingent on successful future raises or partner deals rather than sustainable internal cash generation.
Actinogen Medical News
ACW FAQ
What was Actinogen Medical Limited’s price range in the past 12 months?
Actinogen Medical Limited lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.
What is Actinogen Medical Limited’s market cap?
Actinogen Medical Limited’s market cap is AU$118.95M.
When is Actinogen Medical Limited’s upcoming earnings report date?
Actinogen Medical Limited’s upcoming earnings report date is Aug 31, 2026 which is in 64 days.
How were Actinogen Medical Limited’s earnings last quarter?
Actinogen Medical Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Actinogen Medical Limited overvalued?
According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued.
Does Actinogen Medical Limited pay dividends?
Actinogen Medical Limited does not currently pay dividends.
What is Actinogen Medical Limited’s EPS estimate?
Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinogen Medical Limited have?
Actinogen Medical Limited has 3,717,091,600 shares outstanding.
What happened to Actinogen Medical Limited’s price movement after its last earnings report?
Actinogen Medical Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Actinogen Medical Limited?
Currently, no hedge funds are holding shares in AU:ACW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Actinogen Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.08 (100.00% Upside)
AU$0.08 (100.00% Upside)
Blogger Sentiment
Bullish
AU:ACW Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$667.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-134.14%
Trailing 12-Months
Asset Growth
-55.10%
Trailing 12-Months
Company Description
Actinogen Medical Limited
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
ACW Stock 12 Month Forecast
Average Price Target
AU$0.08
▲(100.00% Upside)
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Alterity Therapeutics
―
Zelira Therapeutics
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---